About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Aug 31, 2020 4:15 pm | Biotechnology
Nestle Health Science, a global business unit of Nestle S.A. (SWX: NESN), has announced a takeover of California-based Aimmune Therapeutics, Inc. (NASDAQ: AIMT) valued at $2.6 billion. Aimmune Therapeutics is a biopharmaceutical company developing and commercializing... Read More »
by Dylan Sammut | Aug 27, 2020 4:06 pm | Healthcare Market Updates
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date... Read More »
by Dylan Sammut | Aug 24, 2020 5:10 pm | Laboratories, MRI & Dialysis
In early March, Thermo Fisher Scientific Inc. (NYSE: TMO) announced a takeover QIAGEN N.V. (NYSE: QGEN) for $11.5 billion, or $43.64 per share in cash. The offer seemed high enough, as the target company only generated revenues of $1.53 billion in 2019, but the... Read More »
by Dylan Sammut | Aug 24, 2020 5:07 pm | eHealth
Vocera Communications, Inc. (NYSE: VCRA), a mobile technology company serving the healthcare market, has expanded its patient engagement platform through a new acquisition. Last week, Vocera purchased a 100% interest in EASE Applications, LLC for $25 million in cash.... Read More »
by Dylan Sammut | Aug 24, 2020 5:06 pm | Biotechnology, Pharmaceuticals
Johnson & Johnson (NYSE: JNJ) made a splash in the healthcare M&A market last week with its acquisition of Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA). The global pharmaceutical giant announced on August 19 it is paying $6.5 billion in cash, or $52.50 per... Read More »